Partnership pairs Piermont’s embedded banking capabilities with MassPay’s global payout expertise to support evolving business payment needs at home and abroad

NEW YORK, Oct. 22, 2026 /PRNewswire-PRWeb/ — Piermont Bank, a digital-first commercial bank, today announced a partnership with MassPay, a fintech and global payout orchestration platform, to help growing businesses move money with speed and confidence, both domestically and across borders.

As businesses grow and expand across markets, they face increasingly complex payment demands—from paying suppliers and marketplace sellers to compensating contractors and distributed workforces through a growing range of payment methods. This partnership brings together Piermont’s robust embedded banking capabilities, including payment rails and settlement services, with MassPay’s payout orchestration platform, which supports payments across more than 180 countries. By combining their respective strengths, the two companies aim to advance payment solutions that keep pace with the evolving needs of growing businesses.

“Successful bank–fintech partnerships start with understanding what each partner does best and how those strengths can come together to solve real business challenges,” said Wendy Cai-Lee, Founder and CEO of Piermont Bank. “At Piermont, we believe banks should provide the trusted financial infrastructure that allows fintech innovators to focus on what they do best—building solutions around their customers’ needs. Our partnership with MassPay reflects that philosophy, combining the strength of regulated banking with specialized payment technology to support business growth.”

MassPay has experienced significant growth in demand for its payout solutions, reporting a 510% year-over-year increase in payout volume in the third quarter of 2026, an indicator of the growing industry need for payout services. As businesses increasingly require flexible payment capabilities across domestic and international markets, the partnership reflects a shared commitment to supporting their evolving financial needs, and by doing so, the parties advance their shared vision to enable SMBs to scale.

“Going cross-border can grow a business significantly, but it often feels like a huge task, and even companies already working internationally end up expanding market by market because of onboarding and compliance hurdles,” said Ran Grushkowsky, CEO of MassPay. “Our partnership with Piermont Bank closes that gap, giving growing businesses one path to pay people in 180 countries.”

The collaboration underscores Piermont’s commitment to advancing bank–fintech partnerships through its embedded banking platform, enabling fintech companies to build and scale specialized financial solutions while leveraging the bank’s regulated infrastructure and banking expertise.

About Piermont Bank

Piermont Bank is a digital commercial bank with a mission to serve fast growing companies at the speed they need. As the first cloud native commercial bank in the U.S., Piermont was built with modern technological infrastructure that allows us to operate with greater flexibility, efficiency, and scalability. We combined commercial banking expertise with innovative technology to deliver integrated and customized solutions to fast growing companies. At Piermont, we are purpose-driven, responsive and practical, building a bank for today’s entrepreneurs and tomorrow’s industry giant. More information can be found at www.PiermontBank.com, or contact hell@PiermontBank.com

About MassPay

We care about your people getting paid, everywhere. MassPay is a global financial platform that lets businesses move money instantly, compliantly, and at scale. With a single, easy-to-integrate API, MassPay connects businesses to local rails, stablecoins, mobile wallets, and real-time payout methods across 180 countries, including bank transfers, digital wallets, debit cards, cash pickup, and crypto. With embedded compliance and KYC, no contract lock-in, and no fees on failed transactions, MassPay serves marketplaces, direct selling organizations, creator platforms, and any business that needs reliable, scalable global payouts. Learn more at masspay.io.

Media Contact

Bill McCue, Piermont Bank, 1 7182087391, bill.mccue@gmail.com, www.piermontbank.com

View original content:https://www.prweb.com/releases/piermont-bank-and-masspay-partner-to-advance-payments-for-growing-businesses-302916899.html

SOURCE Piermont Bank

Partnership pairs Piermont’s embedded banking capabilities with MassPay’s global payout expertise to support evolving business payment needs at home and abroad

NEW YORK, Oct. 22, 2026 /PRNewswire-PRWeb/ — Piermont Bank, a digital-first commercial bank, today announced a partnership with MassPay, a fintech and global payout orchestration platform, to help growing businesses move money with speed and confidence, both domestically and across borders.

As businesses grow and expand across markets, they face increasingly complex payment demands—from paying suppliers and marketplace sellers to compensating contractors and distributed workforces through a growing range of payment methods. This partnership brings together Piermont’s robust embedded banking capabilities, including payment rails and settlement services, with MassPay’s payout orchestration platform, which supports payments across more than 180 countries. By combining their respective strengths, the two companies aim to advance payment solutions that keep pace with the evolving needs of growing businesses.

“Successful bank–fintech partnerships start with understanding what each partner does best and how those strengths can come together to solve real business challenges,” said Wendy Cai-Lee, Founder and CEO of Piermont Bank. “At Piermont, we believe banks should provide the trusted financial infrastructure that allows fintech innovators to focus on what they do best—building solutions around their customers’ needs. Our partnership with MassPay reflects that philosophy, combining the strength of regulated banking with specialized payment technology to support business growth.”

MassPay has experienced significant growth in demand for its payout solutions, reporting a 510% year-over-year increase in payout volume in the third quarter of 2026, an indicator of the growing industry need for payout services. As businesses increasingly require flexible payment capabilities across domestic and international markets, the partnership reflects a shared commitment to supporting their evolving financial needs, and by doing so, the parties advance their shared vision to enable SMBs to scale.

“Going cross-border can grow a business significantly, but it often feels like a huge task, and even companies already working internationally end up expanding market by market because of onboarding and compliance hurdles,” said Ran Grushkowsky, CEO of MassPay. “Our partnership with Piermont Bank closes that gap, giving growing businesses one path to pay people in 180 countries.”

The collaboration underscores Piermont’s commitment to advancing bank–fintech partnerships through its embedded banking platform, enabling fintech companies to build and scale specialized financial solutions while leveraging the bank’s regulated infrastructure and banking expertise.

About Piermont Bank

Piermont Bank is a digital commercial bank with a mission to serve fast growing companies at the speed they need. As the first cloud native commercial bank in the U.S., Piermont was built with modern technological infrastructure that allows us to operate with greater flexibility, efficiency, and scalability. We combined commercial banking expertise with innovative technology to deliver integrated and customized solutions to fast growing companies. At Piermont, we are purpose-driven, responsive and practical, building a bank for today’s entrepreneurs and tomorrow’s industry giant. More information can be found at www.PiermontBank.com, or contact hell@PiermontBank.com

About MassPay

We care about your people getting paid, everywhere. MassPay is a global financial platform that lets businesses move money instantly, compliantly, and at scale. With a single, easy-to-integrate API, MassPay connects businesses to local rails, stablecoins, mobile wallets, and real-time payout methods across 180 countries, including bank transfers, digital wallets, debit cards, cash pickup, and crypto. With embedded compliance and KYC, no contract lock-in, and no fees on failed transactions, MassPay serves marketplaces, direct selling organizations, creator platforms, and any business that needs reliable, scalable global payouts. Learn more at masspay.io.

Media Contact

Bill McCue, Piermont Bank, 1 7182087391, bill.mccue@gmail.com, www.piermontbank.com

View original content:https://www.prweb.com/releases/piermont-bank-and-masspay-partner-to-advance-payments-for-growing-businesses-302916899.html

SOURCE Piermont Bank

Peer-reviewed study reports 12 hours of reproducible continuous AAV8 purification, with final product pools reaching 79% full-capsid enrichment

VIENNA, Va., Oct. 22, 2026 /PRNewswire/ — PAK BioSolutions today announced the publication of a peer-reviewed study on integrated, continuous purification of adeno-associated virus serotype 8 (AAV8) using the PAK PD™ Process Development Scale Continuous Purification System. Conducted in collaboration with iBET – Instituto de Biologia Experimental e Tecnológica, the study, “Streamlining AAV8 Purification with Cyclic Integrated Capture–Polishing Chromatography,” was published in Separation and Purification Technology.

The research team developed an integrated capture and polishing process for AAV8 under repeated cycling operation. The process was operated for 12 hours with reproducible, stable cycle-to-cycle performance. It achieved full-capsid enrichment and impurity reduction comparable to that reported for established batch processes, demonstrating the feasibility of integrated continuous downstream processing for viral vectors.

Why Continuous Downstream Processing Matters for AAV

AAV vectors are a leading platform for in vivo gene therapy, underpinning several approved treatments and a growing pipeline of clinical programs. As these therapies advance toward commercialization, increasing clinical adoption and higher dosing requirements are placing greater demands on downstream processing. Manufacturers need to increase throughput while maintaining product quality.

Process intensification offers a way forward, but continuous operation has largely been limited to individual purification steps, with continuous capture typically paired with batch polishing. This study brings capture and polishing together in a single integrated continuous process.

Capture and Polishing in One Process

The team combined AAVX affinity capture with Mustang® Q anion-exchange membrane polishing, using two alternating columns at each step. As one column loaded, the other underwent elution and regeneration. PAK’s automation coordinated column switching, inline dilution of the capture eluate, and transfer to the polishing step, enabling capture and polishing to operate in parallel.

“This study brings integrated, continuous downstream processing to AAV purification, helping gene therapy manufacturers move toward more efficient manufacturing strategies,” said Joanna Pezzini, CEO of PAK BioSolutions.

Continuous AAV8 Purification Results

Over 12 hours of stable, cycle-to-cycle operation, the integrated process:

Achieved full-capsid enrichment from 34% after affinity capture to 79% in the final polished product poolsRecovered 44% of vector genomes from feed to final poolReduced dsDNA to below the assay detection limit after capture, and host cell protein to below the detection limit after polishing

The continuous purification process implemented on a PAK PD™ system achieved product quality consistent with that reported for established batch AAV purification workflows employing affinity capture and anion-exchange (AEX) polishing. The final full-capsid content of 79% falls within the 68–81% range reported for batch anion-exchange polishing of AAV8. The authors note that batch AAV purification workflows can be translated into an integrated continuous format through defined process adaptation, without requiring custom control development or bespoke system engineering.

Building on PAK BioSolutions’ work with monoclonal antibodies (mAbs), this study extends the body of peer-reviewed research using PAK systems to adeno-associated virus (AAV) vectors. PAK systems were previously used in a 14-day, fully integrated continuous downstream mAb run with AstraZeneca (Ramos et al., Biotechnology and Bioengineering, 2023). PAK systems have also supported GMP clinical manufacturing of drug product, including a First-in-Human (FIH) clinical trial application.

Learn more about the PAK PD™ Process Development Scale Continuous Purification System.

Publication

Ariunbold, E., C. Hall, K. Hill-Byrne, J. Pezzini, C. Peixoto, and R. J. S. Silva. “Streamlining AAV8 Purification with Cyclic Integrated Capture–Polishing Chromatography.” Separation and Purification Technology 415 (2026): 139632. https://doi.org/10.1016/j.seppur.2026.139632

About PAK Systems

PAK Systems are automated, end-to-end continuous purification platforms that run up to four purification stages simultaneously using single-use flow kits. The product line spans the benchtop PAK PD™ for process development, the PAK Pilot™ for pilot and clinical production, and the PAK K-Series™ for commercial manufacturing, so processes can move from development to production on the same technology.

About PAK BioSolutions

PAK BioSolutions is a bioprocessing technology company advancing continuous manufacturing solutions for biopharmaceutical production. The PAK SYSTEM enables GMP-grade, scalable, and efficient drug manufacturing across process development, clinical, and commercial applications. For more information, visit www.pakbiosolutions.com.

Media Contact:
Caroline Hannache
Summit & Vale Consulting, on behalf of PAK BioSolutions
channache@summit-vale.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/pak-biosolutions-and-ibet-advance-integrated-continuous-aav8-purification-302917199.html

SOURCE PAK BioSolutions, Inc.